Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, peak sales outlook, and key risks.
Travere Therapeutics: Still Undervalued Post FSGS Approval
Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, peak sales outlook, and key risks.